December 4, 2024
Legit or not? ABC News looks at the difference
ABC News turned to APC for insight into the difference between legit GLP-1 compounders and fly-by-night 'wellness' sites.
November 25, 2024
Covering the GLP-1 shortage
Reuters did an excellent job updating the status of the Wegovy shortage.
November 22, 2024
End Drug Shortages Act intro’d in Congress
The legislation would expand the sources the FDA may use to declare drug shortages.
November 22, 2024
FDA tirzepatide ‘reconsideration’ period extended
FDA agreed to extend until December 19 a final report on tirzepatide availability to the court.
November 22, 2024
NPR hits the GLP-1 nail on the head
A National Public Radio piece this week tackled the issue of compounded GLP-1 drugs and got the facts and nuance just right.
November 21, 2024
NPR hits the GLP-1 nail on the head
National Public Radio did a spot-on job explaining the current situation with compounded GLP-1 drugs.
November 8, 2024
APC to FDA: Just say no to Lilly
This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list.
November 8, 2024
CC: October 8, 2024
Whispering and shouting, responding to Lilly’s DDC letter, and more
November 8, 2024
California BOP sends proposed compounding regs to comment period
The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period.
November 8, 2024
Checking in on the post-Chevron fallout
What’s happened in the world of federal regulation since the end of Chevron?
November 1, 2024
PFMs can get 2.5% credit card processing
A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%.
November 1, 2024
Phoenix compounders, rise!
The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5.
November 1, 2024
APC election results: directors and bylaws
See the results of APC's elections, including four new directors and several changes to our bylaws.
November 1, 2024
You don’t have to miss our GLP-1 briefing
Our briefing, “What's Up with GLP-1 Compounding (And What's Next)?” is now available on demand.
November 1, 2024
PCAC votes against four nominated bulk drug substances
FDA’s Pharmacy Compounding Advisory Committee voted at a meeting Tuesday against adding four substances to the 503A bulks list.
November 1, 2024
Did someone mention glass houses?
Oopsie! The FDA has cited Novo Nordisk for “quality lapses” at one of the company’s two Ozempic manufacturing plants.
November 1, 2024
GLP-1s: Keep your patients informed
The P3 October newsletter is perfect for explaining GLP-1s to your patients.
November 1, 2024
Sterile compounders: Check your ingredients
FDA issued a reminder this week to only produce sterile drugs with suitable components.
October 30, 2024
Not holding back
We pull no punches in this article about Novo's latest shenanigans
October 30, 2024
Video appearance: APC talks the legal issues
APC CEO Scott Brunner was a guest on "On The Pen" — a YouTube channel dedicated to all things GLP-1.
October 25, 2024
Full of sound and fury, signifying nothing
Novo Nordisk tried to convince the FDA that semaglutide injections are difficult to compound. (Spoiler: They aren't.)
October 24, 2024
PharmExec features APC execs talking about the compounding process
From the manufacturing process to patient and provider challenges, this PharmExec video interview covers all things compounding.
October 24, 2024
APC calls out Novo in Reuters
Reuters used our comment that there's a difference between making molecules and compounding with them.
October 23, 2024
CBS quotes APC on resolving shortages
Taking a different angle, this article looked how the FDA decides when to resolve a shortage.
October 23, 2024
The Brits could have done better
UK-based pharmaphorum is covering the GLP-1 issue, but it played down our rather important point about the ease of compounding with the drugs.
October 17, 2024
FDA issues IV fluids emergency guidance
The FDA has published emergency guidance that empowers pharmacies to help address the nationwide IV solutions shortage.
October 15, 2024
FDA reconsiders on tirzepatide, big questions remain
After a court order, the FDA agreed to reconsider taking tirzepatide off the shortage list.
October 11, 2024
Tirzepatide fallout in The Hill
The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision.
